A5057504926- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Photoreceptor and optogenetics research
- Lymphoma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Neuroscience and Neuropharmacology Research
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Viral-associated cancers and disorders
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Nicotinic Acetylcholine Receptors Study
- Chemical Reactions and Isotopes
- Cancer Research and Treatments
- Metabolomics and Mass Spectrometry Studies
- Advanced NMR Techniques and Applications
- Cervical Cancer and HPV Research
- Immunotherapy and Immune Responses
- Mass Spectrometry Techniques and Applications
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- bioluminescence and chemiluminescence research
Hospital Universitari Germans Trias i Pujol
2014-2025
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol
2013-2023
Universitat Autònoma de Barcelona
1993-2015
Institut Català d'Oncologia
2010
Hôpital Larrey
2009
Complejo Hospitalario Universitario de Santiago
2008
Hospital Clínico Universitario de Valladolid
2006
University of Cambridge
2002-2005
Universitat Politècnica de Catalunya
2002
Abstract Background Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide 6 cycles, although the optimal number of cycles has long been a subject debate. We performed phase II randomized trial investigating whether extending more than improved outcome. Methods Glioblastoma patients treated at 20 Spanish hospitals who had not progressed after were centrally to stop (control arm) or continue (experimental up total 12 same doses they receiving in cycle 6....
We explored the rationale for treating glioblastoma (GBM) with regorafenib. In 103 newly diagnosed GBM patients, we assessed mutations, copy number variants (CNVs), fusions, and overexpression in 46 genes encoding protein kinases (PKs) potentially targeted by regorafenib or its metabolites performed a functional enrichment analysis to assess their implications angiogenesis. analyzed regorafenib’s binding inhibitory activity target affinity these PKs focused on subset of 18 inhibited at...
Tapia G, Lopez R, Muñoz-Mármol A M, Mate J L, Sanz C, Marginet Navarro J-T, Ribera J-M & Ariza (2011) Histopathology59, 672–678 Immunohistochemical detection of MYC protein correlates with gene status in aggressive B cell lymphomas Aims: translocation entails a bad prognosis and poor response to rituximab–cyclophosphamide, doxorubicin, vincristine prednisone (R-CHOP) diffuse large (DLBCL), more intensive chemotherapy regimens could be effective those cases. Its evaluation requires...
To assess how hybridization probe design may affect MYC status determination in Burkitt lymphoma and diffuse large B-cell lymphoma.We compared the results obtained with one dual-fusion two break-apart commercial probes a retrospective series of 91 aggressive lymphomas. All three were able to detect IGH-MYC translocation every case bearing it (13/13). However, seven 13 (54%) non-IGH-MYC (light-chain immunoglobulin or non-immunoglobulin-MYC) rearrangements unambiguously detected by just...
Abstract Circulating biomarkers in blood may provide an interesting alternative to risky tissue biopsies the diagnosis and follow-up of glioblastoma patients. We have assessed MGMT methylation status samples from unresected patients who had been included randomized GENOM-009 trial. Paired were by methylation-specific PCR (MSP) pyrosequencing (PYR). After establishing minimum PYR cut-off that could yield a significant difference overall survival, we sensitivity, specificity, positive...
Primary renal cell carcinoma (RCC) is the most frequent kidney cancer. In transplant patients, RCC more commonly arise in native kidneys, whereas allograft involvement has been just occasionally reported. these latter cases, a graft origin of tumor cells should be considered and other recipients from same donor investigated. So far, genetic studies to trace cancer have always confirmed tumors.A 58-year-old man developed an grafted 14 years after transplantation. Histologic...
MYC and BCL2 gene translocations protein expression have recently demonstrated to be of prognostic significance in systemic diffuse large B‐cell lymphoma (DLBCL). However, their role primary central nervous system DLBCL (CNS‐DLBCL) prognosis has been scarcely analyzed. We studied the immunophenotype, status , BCL2, BCL6 genes clinical features a series 42 CNS‐DLBCL evaluated significance. found high 43% cases, this was associated with lower overall survival (OS). Cases concurrent showed OS,...
Neoadjuvant treatment (NAT) is one of the most widely used options for HER2+ and triple negative (TN) early breast cancer (BC). Since around half patients treated with NAT do not achieve a pathologically complete response (pCR), biomarkers to predict resistance are urgently needed. The correlation clinicopathological factors pCR was studied in 150 (HER2 = 81; TN 69) pre- post-NAT differences tumour were compared. Low estrogen receptor (ER) expression, high tumour-infiltrating lymphocytes...
Tapia G, Sanz C, Mate J L, Muñoz‐Mármol A M & Ariza (2012) Histopathology 60, 768–773 Improved clonality detection in Hodgkin lymphoma using the BIOMED‐2‐based heavy and kappa chain assay: a paraffin‐embedded tissue study Aims: Although BIOMED‐2 polymerase reaction (PCR) standardization protocols allow nearly 100% of non‐Hodgkin B cell lymphomas, they have not been widely validated for (HL). Our aim was to assess protocol sensitivity when non‐microdissected, formalin‐fixed, (FFPE) from...
// Marta Domènech 1 , 3 Ana M. Muñoz Marmol 2 Jose Luis Mate Anna Estival Teresa Moran Marc Cucurull Maria Saigi Ainhoa Hernandez Carolina Sanz Alba Hernandez-Gallego Aintzane Urbizu Martinez-Cardus Adrià Bernat and Enric Carcereny Medical Oncology Department, Catalan Institute of Badalona, Germans Trias i Pujol Hospital, Barcelona, Spain Pathology Badalona Applied Research Group in (BARGO), Institut d'Investigació en Ciències de la Salut (IGTP),...
Single and multiple mutants of extracellular Glu side chains bacteriorhodopsin were analyzed by acid calcium titration, differential scanning calorimetry, thermal difference spectrophotometry. Acid titration spectra show that the second group protonating with Asp<sup>85</sup> is revealed in E204Q absence Cl<sup>−</sup> but not observed triple mutant E9Q/E194Q/E204Q or quadruple E9Q/E74Q/E194Q/E204Q. The results point to Glu<sup>9</sup> as cooperatively Asp<sup>85</sup>. Comparison apparent...
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype in non-immunosuppressed and human immunodeficiency virus (HIV)-positive patients. The prognosis of DLBCL with germinal center (GC) phenotype better than that non-germinal (non-GC) by immunohistochemical expression profile (IHC) some studies but not others. frequency these phenotypic subtypes related to HIV infection well known. objectives this study were characterize IHC tissue microarray 98 patients DLBCL, 34 whom...
The quadruple bacteriorhodopsin (BR) mutant E9Q+E74Q+E194Q+E204Q shows a λ max of about 500 nm in water at neutral pH and great influence salts on the visible absorption spectrum. Accessibility to Schiff base is strongly increased, as detected by rapid bleaching effect hydroxylamine dark well light. Both proton release kinetics photocycle are altered, indicated delayed after uptake changed M kinetics. Moreover, affinity color‐controlling cation(s) found be decreased. We suggest that four Glu...
The aim of this study was to determine how TERTp mutations impact glioblastoma prognosis. Materials and Methods: were assessed in a retrospective cohort 258 uniformly treated patients. RNA-sequencing whole exome sequencing results available subset Results: Overall, there no differences outcomes between patients with mutated TERTp-wt or TERTp. However, we found significant according the type mutation. Progression-free survival (mPFS) 9.1 months for those C250T mutation 7 either C228T (p =...